

Table S1 Analyzed data of finally included patients before baricitinib initiation (n=46).
Mean age (years): 37.1 (12-78)
Sex Female: 34, Male: 12
Mean body weight (kg): 57.6 (44.8-83.6)
Prior treatment before baricitinib initiation
TCS, topical JAKi, topical PDE4i, and/or TCI and oral antihistamines: 44
Biologics: 2
Mean EASI score: 26.9 (16-57.7)
Mean body surface area involvement (%): 38.3 (10-80)
ADCT scores (scored as 0: none, 1: 1-2 days, 2: 3-4 days, 3: 5-6 days, 4: every day)
• Mean score of the 2nd item (frequency of intense itching per week): 3.5 (1-4)
• Mean score of the 4th item (frequency of sleep disturbance due to AD per week): 2.5 (0-4)
• Mean total score: 17.6 (10-24)
Abbreviations: TCS, topical corticosteroids; JAKi, JAK inhibitor; PDE4i, Phosphodiesterase 4 inhibitor, TCI, topical calcineurin inhibitor.

Table S2 Post-treatment data including ADCT scores, treatment continuation or discontinuation, subsequent treatments in discontinued cases, and adverse events.
Mean EASI score after 1-2 weeks of treatment: 18.9 (5.0-43.1)
ADCT scores after 1-2 weeks of treatment (scored as 0: none, 1: 1-2 days, 2: 3-4 days, 3: 5-6 days, 4: every day)
• Mean score of the 2nd item (frequency of intense itching per week): 0.9 (0-2)
• Mean score of the 4th item (frequency of sleep disturbance due to AD per week): 0.5 (0-1)
• Mean total score: 5.3 (0-11)
Baricitinib continuation Yes: 21 (46%; including 3 cases with intermittent administration during flares)
Treatment after baricitinib discontinuation
TCS, topical JAKi, topical PDE4i, and/or TCI and oral antihistamines: 19 (including above 3 cases)
Biologics: 7
Another JAKi: 2
Adverse Events (All symptoms listed below were mild)
Lower abdominal pain: 1
Dizziness, nausea and numbness in limbs: 1
Fatigue and gastrointestinal symptoms: 1
Chest discomfort (non-specific complaints): 1
Acne: 3
Abbreviations: TCS, topical corticosteroids; JAKi, JAK inhibitor; PDE4i, Phosphodiesterase 4 inhibitor, TCI, topical calcineurin inhibitor.